OABI
NASDAQ · Life Sciences Tools & Services
Omniab Inc
$5.07
+0.08 (+1.60%)
Financial Highlights (FY 2026)
Revenue
22.95M
Net Income
-79,617,354
Gross Margin
98.4%
Profit Margin
-347.0%
Rev Growth
-31.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.4% | 98.4% | 31.4% | 31.4% |
| Operating Margin | -369.5% | -332.5% | 6.8% | 7.4% |
| Profit Margin | -347.0% | -329.7% | 5.9% | 5.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 22.95M | 33.69M | 184.39M | 150.46M |
| Gross Profit | 22.57M | 33.14M | 57.85M | 47.20M |
| Operating Income | -84,780,688 | -112,028,511 | 12.45M | 11.10M |
| Net Income | -79,617,354 | -105,205,723 | 10.85M | 8.86M |
| Gross Margin | 98.4% | 98.4% | 31.4% | 31.4% |
| Operating Margin | -369.5% | -332.5% | 6.8% | 7.4% |
| Profit Margin | -347.0% | -329.7% | 5.9% | 5.9% |
| Rev Growth | -31.9% | -31.9% | +2.4% | +24.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 119.74M | 97.60M |
| Total Equity | — | — | 186.51M | 185.21M |
| D/E Ratio | — | — | 0.64 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -68,891,845 | -96,090,519 | 16.49M | 14.30M |
| Free Cash Flow | — | — | 4.93M | 6.48M |